TSR-011: Interim Phase I/IIa data

Additional interim data from an open-label Phase I/IIa in patients with solid tumors showed that TSR-011 for 8 weeks led to a response as measured by RECIST criteria in 3 of 5 ALK inhibitor-naive pati...